Apeloa, founded in 1989, is a publicly traded company as part of the Hengdian Group. Headquartered in Hengdian, Zhejiang, Apeloa has over 7,000 employees worldwide. Apeloa is China's top 2 exporter of APIs and the top 5 CDMO companies. It also ranks 36th among China’s pharmaceutical companies.

Apeloa’s core businesses include APIs, CDMO, Finished Dosage Form, Aesthetic & Care Ingredients, with seven API manufacturing sites (five chemical synthesis and two fermentation) and two drug product sites. Since 2007, our main API manufacturing sites have passed audits by NMPA, US FDA, EMEA, and PMDA, establishing us as a leading API enterprise. Our CDMO business maintains strategic partnerships with top pharmaceutical companies globally, offering comprehensive services and sustaining high growth.

Apleoa implements the development strategy of "Global API Leader, CDMO Excellence, High-quality & Affordable Medicine, Expanding Aesthetic & Care Ingredients", with annual R&D expenses exceeding 5% of revenue. Our philosophy emphasizes technology driven, full compliance, and cost efficiency, aiming to be a global leading technology-driven pharmaceutical manufacturer.